准分子激光消蚀联合药物涂层球囊治疗膝下动脉疾病的临床价值

Outcomes of excimer laser ablation combined with drug-coated balloon for atherosclerotic lesions in below-the-knee arteries

目的:探讨准分子激光联合药涂球囊治疗膝下动脉病变的效果。方法:回顾性分析2019年6月至2022年11月在两个中心接受准分子激光联合药涂球囊治疗的膝下动脉粥样硬化病变的患者的临床资料。结果:共纳入22例患者。病变包括3例(13.6%)狭窄和19例(86.4%)完全闭塞。平均病变长度(25.6±5.7)cm。技术成功率为95.5%。限流性夹层发生率4.5%,植入补救支架。踝肱指数在每个随访时间点均较术前显著改善。中位随访时间21.5个月,1年的一期通畅率为80.3%。结论:准分子激光联合药涂球囊治疗膝下动脉病变安全、有效,显著提高一期通畅率。

Objective To investigate the safety and efficacy of excimer laser ablation(ELA)combined with drug-coated balloon(DCB)for the below-the-knee(BTK)artery lesions.Methods From Jun 2019 to Nov 2022,22 patients receiving ELA combined with DCB in atherosclerotic lesions of BTK artery at these two centers were retrospectively analyzed.Results In these 22 patients there were 3(13.6%)suffering from stenosis and 19(86.4%)from chronic total occlusion(CTO)lesions.The mean length of lesion was(25.6±5.7)cm.The technical success rate was 95.5%.Flow-limiting dissection was found in 1(4.5%)patient and a bailout stent was deployed.The mean ankle-brachial index(ABI)significantly improved during the follow-up period compared with that before the treatment.The median follow-up time was 21.5 months.The 1-year primary patency rate was 80.3%Conclusion ELA combined with DCB was safe and effective in the treatment of atherosclerotic lesions of BTK artery,improving the primary patency.